Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies

• Autor(a) principal: Martins, Sandra
• Data de Publicação: 2011
• Outros Autores: Reis, R. M., Rodrigues, António Mesquita, Baltazar, Fátima, Longatto Filho, Adhemar
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Texto Completo: https://hdl.handle.net/1822/18684
• topic: Angiogenesis; Colorectal cancer; Colorectal cancer treatment; Endoglin; Prognosis; Vascular endo¬thelial growth factor; Science & Technology

Colorectal cancer (CRC) is one of the cancer models and most of the carcinogenic steps are presently well understood. Therefore, successful preventive measures are currently used in medical practice. However, CRC is still an important public health problem as it is the third most common cancer and the fourth most frequent cause of cancer death worldwide. Nowadays, pathologic stage is a unique and well-recognized prognostic indica¬tor, however, more accurate indicators of the biologic behavior of CRC are expected to improve the specificity of medical treatment. Angiogenesis plays an important role in the growth and progression of cancer but its role as a prognostic factor is still controversial. Probably the most important clinical implication of tumor angiogen¬esis is the development of anti-angiogenic therapy. The goal of this review is to critically evaluate the role of angiogenic markers, assessed by either endoglin-related microvessel density or expression of vascular endothelial growth factor family members in the CRC setting and discuss the role of these angiogenic markers in anti-angiogenic therapies.